This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hannedouche, T. Articles by French Collaborative Telmisartan Study Group Search for Related Content PubMed PubMed Citation Articles by Hannedouche, T. Articles by French Collaborative Telmisartan Study Group, Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ENALAPRIL MALEATE FUROSEMIDE Social Bookmarking                         What's this?

Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension

Service de Néphrologie, Hôpital Civil, Strasbourg, France

Jacques Chanard

Service de Néphrologie, Hôpital Maison-Blanche, Reims, France

Bertrand Baumelou

Clinical Research Unit, Boehringer Ingelheim, Reims, France

French Collaborative Telmisartan Study Group

The effect on renal function and efficacy of the angiotensin II AT₁-receptor blocker (ARB), telmisartan, were compared with those of the angiotensin-converting enzyme inhibitor, enalapril, for the treatment of mild-to-moderate hypertension (diastolic blood pressure [DBP] 95—114 mmHg) in the presence of moderate renal failure (creatinine clearance [Ccr] 30—80 ml/minute). The study was multicentre, double-blind, double-dummy and active-controlled in design, with patients randomised in a 2:1 ratio to receive telmisartan or enalapril. After a two-week placebo run-in period, the 71 eligible patients received either telmisartan, 40 mg, or enalapril, 10 mg, once-daily for four weeks. Thereafter, doses were titrated to telmisartan 80 mg or enalapril 20 mg once-daily if supine trough DBP was still 90 mmHg. After a further four weeks, dose titration was again performed, as required, to telmisartan, 80 mg, or enalapril, 20 mg, or frusemide was given in addition if the double dose was already being administered. Mean Ccr decreases of 4.6% for telmisartan and 2.8% for enalapril were not clinically significant. Adverse events occurred in 12 (26.7%) telmisartan-treated patients and in 12 (46.2%) patients receiving enalapril. The mean reduction in supine trough DBP from baseline to the last available value was 12.5 mmHg for telmisartan, compared with 11.9 mmHg for enalapril. A full (reduction of 10 mmHg) or partial (reduction of 7—9 mmHg) response occurred in 78% of telmisartan patients and 65% of enalapril patients. In the enalapril group, 43% of patients required frusemide, compared with 29% of those in the telmisartan group. In conclusion, telmisartan lacks detrimental effect on renal function, is effective in the treatment of mild-to-moderate hypertension in patients with moderate renal failure, and is comparable to enalapril.

Key Words: telmisartan • renal safety • creatinine clearance • enalapril • hypertension

References

• Brunner HR, Waeber B., Nussberg J. In: Messerli F, ed. Angiotensin converting enzyme inhibitor in arterial hypertension. Cardiovascular Drug Therapy. Philadelphia: WB Saunders; 1990:732-60.
• Nelson EB, Harm SC, Goldberg M. et al. Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1995: 2895-916.
• Giatras I., Lau J., Levey AS et al. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-45.[Abstract/Free Full Text]
• Bretzel RG Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997;10(9 Pt 2):208S-17S.[CrossRef][Medline] [Order article via Infotrieve]
• Burnier M., Brunner HR Angiotensin II receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 1994;3: 537-45.[CrossRef][Medline] [Order article via Infotrieve]
• Geiger H. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant 1997;12:640-2.[Free Full Text]
• Materson BJ, Preston RA Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience. Arch Intern Med 1994;154:513-23.[Abstract/Free Full Text]
• Textor SC Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 1997;17:67-76.[Web of Science][Medline] [Order article via Infotrieve]
• Navis G., Faber HJ, de Zeeuw D. et al. ACE-inhibitors and the kidney: a risk-benefit assessment. Drug Saf 1996;15: 200-11.[Web of Science][Medline] [Order article via Infotrieve]
• Devoy MA,Tomson CR, Edmunds ME et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992;232:493-8.[Web of Science][Medline] [Order article via Infotrieve]
• Kon V., Fogo A., Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-50.[Web of Science][Medline] [Order article via Infotrieve]
• Ichikawa I. Angiotensin II receptors and renal hemodynamics and function. Blood Press 1996;2(Suppl):19-21.[Medline] [Order article via Infotrieve]
• Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996;50:684-92.[Web of Science][Medline] [Order article via Infotrieve]
• Physicians' Desk Reference, 51st edition. Montvale, NJ: Medical Economics; 1997.
• Stangier J., Schmid J.,Türck D. et al.Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1312-22.[Abstract]
• Stangier J., Su CAPF, Brickl R. et al. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000;40: 1365-72.[Abstract]
• Weir MR Are drugs that block the renin-angiotensin system effective and safe in the patients with renal insufficiency? Am J Hypertens 1999;12(12 Pt 3):195S-203S.[Web of Science][Medline] [Order article via Infotrieve]
• Food and Drug Administration. International Conference on Harmonization; Draft Guidance on Principles for Clinical Evaluation of New Antihypertensive Drugs; Availability. Federal Register 2000;65:4872-1.
• Hricik DE, Levine BS, Adrogue HJ et al. Evaluation of enalapril/diltiazem ER in hypertensive patients with coexisting renal dysfunction. J Hum Hypertens 1996;10:769-74.[Web of Science][Medline] [Order article via Infotrieve]
• Kramer BK, Schweda F., Ramipril Efficacy in Nephropathy Study. Ramipril in non-diabetic renal failure (REIN study). Lancet 1997;350:736-7.[Medline] [Order article via Infotrieve]
• Gansevoort RT, de Zeeuw D., de Jong PE Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.[Web of Science][Medline] [Order article via Infotrieve]
• Nielsen S., Dollerup J., Nielsen B. et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril-controlled 3 months' study. Nephrol Dial Transplant 1997;12(Suppl 2):19-23.[Free Full Text]
• Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998;15:229-40.[Web of Science]
• Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
• Gomez HJ, Cirillo VJ, Irvin JD Enalapril.A review of human pharmacology. Drugs 1985;30(Suppl 1):13-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Oguchi H., Miyasaka M., Koiwai T. et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet 1993;24:421-7.[Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 4, 246-254 (2001)
DOI: 10.3317/jraas.2001.039


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Barnett Preventing Renal Complications in Type 2 Diabetes: Results of the Diabetics Exposed to Telmisartan and Enalapril Trial J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S132 - S135. [Abstract] [Full Text] [PDF]

				A.M. Sharma Renal involvement in hypertensive cardiovascular disease Eur. Heart J. Suppl., August 1, 2003; 5(suppl_F): F12 - F18. [Abstract] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hannedouche, T. Articles by French Collaborative Telmisartan Study Group Search for Related Content PubMed PubMed Citation Articles by Hannedouche, T. Articles by French Collaborative Telmisartan Study Group, Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ENALAPRIL MALEATE FUROSEMIDE Social Bookmarking                         What's this?